What Happened

BioNTech announced plans to close three German manufacturing sites—in Idar-Oberstein, Marburg, and Tübingen (the former CureVac HQ)—plus its Singapore plant after failing to find buyers. The company had explored divestment options since May 2026 but said a sale was not possible despite intensive efforts. The closures will affect up to 1,800 jobs and generate €500 million in annual cost savings, which BioNTech plans to reinvest into its oncology pipeline.

Who Is Affected

The job cuts impact employees at the three German sites and the Singapore facility, as well as some CureVac sites abroad acquired in the $1.25 billion deal in 2025. Affected locations include Idar-Oberstein (closing end of 2028), Marburg (early 2028), Tübingen (end of 2027), and Singapore (Q1 2027). Separately, BioNTech successfully sold its peptide CDMO subsidiary JPT Peptide Technologies to Dubag Group in August 2026.

Market Impact

The closures mark a significant downsizing of Germany's mRNA manufacturing capacity, signaling the post-COVID demand shift. Competitors are also restructuring:

• Moderna extended its cost-savings initiative to 2027, targeting $4.2B in operating costs vs $6.3B in 2024, after ramping down production at Lonza's Swiss site.
• GSK is closing an egg-based flu vaccine plant in Dresden due to reduced demand for traditional flu shots, while advancing an mRNA flu vaccine candidate.
• The FDA approved Moderna's first mRNA influenza vaccine (mFlusiva), but CDC inaction on a recommendation has created uncertainty.

What to Watch

Key developments to monitor: whether BioNTech finds a buyer for its Singapore site by the end of September 2026; the timeline for actual site exits (Tübingen end-2027, Marburg early-2028, Idar-Oberstein end-2028); how BioNTech's reinvestment in oncology pipeline commercialization drives vendor needs; and regulatory decisions—especially CDC recommendations for mRNA flu vaccines—that could reshape the market.

Related coverage

• Bristol Myers cuts another 265 jobs tied to New Jersey headquarters
• Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
• Novo Nordisk workforce reduction reaches 13,000 amid R&D restructuring
• BMS lays off 265 New Jersey staff amid ongoing reorganization